approximately $
5.3
billion of which $
3.7
billion is associated with the Biopharma segment.
From the start of this program through March 30, 2025, we incurred total costs under this program of $
3.2
billion, of which $
2.7
billion is associated with our Biopharma segment (including $
2.5
billion of restructuring charges).
B. Manufacturing Optimization Program
In the second quarter of 2024, we announced that we launched a multi-year, multi-phased program to reduce our costs of goods sold, which is expected to include operational efficiencies, network structure changes, and product portfolio enhancements. The first phase of this program is focused on operational efficiencies and we expect costs for this first phase to total approximately $
1.6
billion, primarily representing cash expenditures for severance and implementation costs, all of which is associated with our Biopharma segment. From the start of this program through March 30, 2025, we incurred costs under this program of $
1.2
billion, substantially all of which is restructuring costs for our Biopharma segment. These costs were recorded primarily in 2024, with cash outlays expected primarily in 2025 and 2026.
11
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
C. Key Activities
(a)
In 2025, primarily represents cost-reduction initiatives. In 2024, primarily represented Seagen acquisition-related costs, largely offset by credits for cost-reduction initiatives. Amounts associated with our Biopharma segment: charges of $
617
million for the three months ended March 30, 2025 (including charges of $
587
million for our Realigning our Cost Base Program and credits of $
4
million for our Manufacturing Optimization Program) and credits of $
37
million for the three months ended March 31, 2024 for our Realigning our Cost Base Program.
(b)
Represents external costs for banking, legal, accounting and other similar services.
(c)
Represents external, incremental costs directly related to integrating acquired businesses, such as expenditures for consulting and the integration of systems and processes, and certain other qualifying costs.
(d)
Represents the impact of changes in the estimated useful lives of assets involved in restructuring actions.
(e)
Represents incremental costs directly related to implementing our non-acquisition-related cost-reduction/productivity initiatives.
(a)
Included in
Other current liabilities
($
1.7
billion) and
Other noncurrent liabilities
($
437
million).
(b)
Other activity includes adjustments for foreign currency translation that are not material to our condensed consolidated financial statements.
(c)
Included in
Other current liabilities
($
1.8
billion) and
Other noncurrent liabilities
($
562
million).
12
PFIZER INC. AND SUBSIDIARY COMPANIES
NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
(UNAUDITED)
Note 4.
Other (Income)/Deductions—Net
(a)
The decrease in net interest expense in the first quarter of 2025,